Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 11/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691032 | 0.93 | CXCR4 (0.36) | CXCR4HDAC1HDAC6ADORA2AFNTA | |
| SCHEMBL6018467 | 0.91 | CXCR4 (0.36) | CXCR4HDAC1HDAC6ADORA2AFNTA | |
| SCHEMBL6018114 | 0.90 | CXCR4 (0.36) | CXCR4HDAC1HDAC6ADORA2AFNTA | |
| SCHEMBL6018194 | 0.89 | FNTA (0.38) | CXCR4HDAC1HDAC6ADORA2AFNTA | |
| SCHEMBL6018210 | 0.88 | CXCR4 (0.39) | CXCR4HDAC1HDAC6CASRADORA2A | |
| SCHEMBL6018202 | 0.82 | CXCR4 (0.47) | CXCR4HDAC1HDAC6CASRADORA2A | |
| SCHEMBL6018557 | 0.81 | HDAC1 (0.43) | CXCR4HDAC1HDAC6CASRADORA2A | |
| SCHEMBL6681750 | 0.81 | HDAC1 (0.54) | CXCR4HDAC1HDAC6CASRADORA2A | |
| SCHEMBL6018964 | 0.81 | CXCR4 (0.38) | CXCR4HDAC1HDAC6ADORA2AXIAP | |
| SCHEMBL6018478 | 0.81 | CXCR4 (0.36) | CXCR4HDAC1HDAC6ADORA2AFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | CXCR4 2185/4885HDAC1 651/4885HDAC6 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.